About Veratrak

Veratrak is an award-winning software solution for the life science industry. It offers secure and compliant document transfer and facilitates collaboration between supply chain partners to generate efficiencies across operations.

With the aim to move companies from paper to platform, the solution was developed by experts and aims to drive a digital transformation to create a safer, more secure future for the industry’s critical supply chains.
As the first company in the world to offer a live blockchain solution for the pharmaceutical industry and co-founding members of the EPOCH initiative, Veratrak is at the forefront of blockchain technology and its potential to benefit security, collaboration and operational performance.

Mission & Vision for the Future

The Veratrak team is dedicated to transforming supply chain efficiency and compliance by moving companies from paper to platform. We do this by using modern technology and following best-in-class quality standards to drive visibility, collaboration, and the reduction of working capital for all our partners.

We are genuinely excited to bring innovative solutions that work for our partners to the table. We have an intelligent and committed team that helps companies adopt a proactive approach to cybersecurity. We bring new energy and flexibility to organisations. We know that the status-quo isn’t fit-for-purpose and we aspire to drive supply chains forward.

Our Values

We are team players

To be reliable and respectful to colleagues and customers

We demonstrate commitment to our team and our customers, offering support as standard and always there for you when you need us. We are eager to develop our own skills and the skills of those around us. Collaboration is at the core of what we do.

We are driven

We have a positive and enthusiastic attitude, always aiming to excel at what we do.

We believe in our work and are passionate about our solution and our customers. We demonstrate initiative day in, day out and proactively work to solve any problems. We are truly motivated to always deliver on our promises.

We are versatile

Agile and flexible, we adapt to every customer.

We know that no two projects are the same, so we work to find the best and most efficient way to meet their requirements. We are resourceful and skilled at what we do and we continually improve our offering for customers. We want to be better than yesterday.

We are genuine

We are always open and honest with colleagues and customers.

We believe in our product one-hundred percent and we communicate that directly and sincerely. We understand the importance of building trust across our team and with our partners to give them peace of mind. We are true to our word.


Jason Lacombe - Chief Executive Officer

Jason leads strategy, partnerships and sales at Veratrak. Prior to Veratrak, Jason was a health economist building microsimulation models for the drug supply chain. Jason first became interested in blockchain technology while studying a PhD at the University of Oxford, where he held an executive role on the blockchain society. Jason has also been an Expert Advisor to the European Parliament and member of a World Health Organisation Collaborating Centre. Most recently, Jason was selected to the Forbes 30 Under 30, and as a blockchain influencer by the UK Parliamentary Group on Blockchain.

Colin Tierney - Head of Product

Colin manages product development and strategy for Veratrak. Prior to joining Veratrak, Colin managed the flagship product line for the market-leading U.S. surgical inventory management software, ABACUS, for over 3 years, encompassing over 6 years of experience in product and operations in medical software. Colin delivered leading track and trace SaaS and mobile technology used at 12 of the top 20 U.S. healthcare systems at Applied Logic prior to the firm's strategic acquisition by Censis Technologies in 2018. Colin holds an MBA from the University of Oxford, Saïd Business School and a BA from the University of Missouri.

Roland Becsi - Head of Engineering

Roland leads the engineering team at Veratrak. Roland is an experienced full-stack product developer with over 10 years experience working in a senior role on enterprise projects within the pharmaceutical sector, insurance, technology and blockchain space. Prior to Veratrak, Roland was a Senior Engineer at a digital consultancy and was responsible for building and leading a team of 12 that implemented the first end-to-end electronic medical health records blockchain application. Always up to date with the latest technologies, some of his skills include Angular, React, NodeJS, PHP and Continuous Integration to Amazon Web Services.

Advisory Board

Veratrak is supported by an advisory board with vast experience across the pharmaceutical industry, as well as insight into the supply chain, packaging, manufacturing and new technologies.

Charles Songhurst

Charles is a consummate insider in the tech scene and a leading technology investor. He previously worked at Microsoft as head of Global strategy, reporting directly to the CEO. Charlie directed the acquisition of both Yahoo and Skype and, alongside Bill Gates, negotiated Microsoft’s entry into Facebook. Charles now manages his own VC which has large stakes in the quantum computing, biotech, space and enterprise SaaS industries.

Dr. Heinrich Zetlmayer

Heinrich Zetlmayer, General Partner at Blockchain Valley Ventures, is an accomplished digital investor and board member. With more than 20 years experience in Supply Chain Management and Operations, Heinrich was a VP at IBM's Global Business Services leading Supply Chain and Operations Management Services in EMEA.

Tony Fitzpatrick

Tony brings over 30 years of strategic, supply chain, and operations experience in the logistics, pharmaceutical and medical device industries. Currently, Tony is EVP Operations at Vectura Group, and previously worked at Baxter for 18 years including serving as VP Global Supply Chain, and VP Operations EMEA.

David Buller

David Buller is an entrepreneur, angel investor, CEO at Buller Invest, and Venture Partner at Ascension Ventures. An entrepreneur since the age of 15, David founded Avantec (hospital supplies and pharmacy automation), which was acquired by Omnicell in 2015. He works with investors, syndicates, VCs, accelerators and startups in the UK, Europe and USA as a startup advisor and mentor, supporting startups raise capital and investors find funds and deal-flow.

Antonin de Fougerolles

Antonin de Fougerolles is the CEO of Evox Therapeutics and a Venture Partner at Ascension Ventures with over 20 years’ experience in the pharmaceutical and biotechnology industry. He has a background in developing transformative therapeutic drug platforms in the nucleic acid and biologics space. His expertise has led to the progression of multiple assets through clinical trials. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. He holds a PhD in Immunology from Harvard University.

Agash Navaranjan

Agash Navaranjan is an experienced technologist in the Blockchain space. Currently the CTO of DoveTail Lab working on creating audit trails for medical data transfer. Previously Agash ran a Blockchain consultancy working with clients such as HSBC, Rabo Bank and various startups working with using Ethereum and Hyperledger Fabric.

Dexter Tjoa

Dexter is an experienced senior executive in the pharmaceutical industry. Currently, he is Director Corporate Strategy at Tjoapack, a leading pharmaceutical contract services organisation, reporting directly to the CEO. He is responsible for business strategy and growth of the company. Dexter brings supply chain, commercial, and technology expertise with a track record of leading large innovation and change projects. He holds an MSc in mathematics and computer science from the University of Oxford and has previously worked in technology sector.

David Evans

David is a highly driven and energetic leader, with over 30 years of experience in the deployment of innovative and sustainable solutions for the pharmaceutical sector. David has previously worked as Head of End to End Supply Chain Design at Merck, and as a Global Strategy and Innovation Director of GSK. David brings an extensive track record of leading major initiatives, including systems deployment projects, restructuring organisational functions, strategy development and deployment.

Dr. Mike Bogetofte Barnkob

Mike is a clinical doctor utilizing cellular therapies to combat cancer. He has 10 years of experience in tumour-immunology and is extensively involved in establishing a pipeline for delivering advanced therapy medicinal products in the Netherlands. He has received several awards, including the Ita Askonas medal. Mike completed his medical degree at Odense University Hospital, studied at Massachusetts Institute of Technology and holds a PhD in medical sciences from the University of Oxford.

Professor Richard W. Barker

Richard is Founding Director of New Medicine Partners and chairman of the South London Health Innovation Network. He also chairs Metadvice, and is a board member of Image Analysis, and of Celgene. He founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI). The senior roles he previously held include: Director General of the Association of the British Pharmaceutical Industry, GM of Healthcare Solutions for IBM, CEO of Chiron Diagnostics and head of McKinsey's European healthcare practice.

Stephen Allott

Stephen is a Venture Partner at Seedcamp, author of Sales Tales and is the Founder of the Cambridge University Computer Lab Ring. Stephen was President, CFO and a main board director of Micromuse (NASDAQ: MUSE). Reaching $7 billion market cap, MUSE is the most valuable organically grown UK origin software company to date. He has worked for Xerox, Sun Microsystems, McKinsey & Company, Red Gate Software and the Cabinet Office growing the G-Cloud Digital Marketplace to over £6 billion in sales.

Lindon Potter

Lindon has 10 years of experience in the pharmaceutical and healthcare sectors, including seven years of experience in quality assurance (QA), where he specialises in providing support associated with clinical trial conduct, medicinal product manufacturing, medicinal product distribution and pharmacovigilance. Lindon has held QA positions with various organisations including contract research organizations and pharmaceutical companies. Lindon has been operating as an independent consultant since 2017 providing GCP, GPvP, GDP and GMP QA and regulatory compliance services to customers.